Syndemic Characterization of HCV, HBV, and HIV Co-infections in a Large Population Based Cohort Study
- PMID: 31193601
- PMCID: PMC6537523
- DOI: 10.1016/j.eclinm.2018.10.006
Syndemic Characterization of HCV, HBV, and HIV Co-infections in a Large Population Based Cohort Study
Abstract
Background: Limited data are available on HBV, HCV, and HIV co-infections and triple infection. We characterized co-occurrence of HIV, HBV, and HCV infections at the population level in British Columbia (BC) to identify patterns of predisposing factors unique to co-infection subgroups.
Methods: We analyzed data from the BC Hepatitis Testers Cohort, which includes all individuals tested for HCV or HIV in BC between 1992 and 2013, or included in provincial public health registries of HIV, HCV, HBV, and active tuberculosis. Individuals were classified as negative, mono-, and co-infection groups based on HIV, HBV, and HCV status. We evaluated associations between risk factors (injection drug use, sexual orientation etc.) and co-infection groups using multivariate multinomial logistic regression.
Findings: Of a total of 1,376,989 individuals included in the analysis, 1,276,290 were negative and 100,699 were positive for HIV, HBV, and/or HCV. Most cases (91,399, 90.8%) were mono-infected, while 3991 (4.0%) had HBV/HCV, 670 HBV/HIV (0.7%), 3459 HCV/HIV (3.4%), and 1180 HBV/HCV/HIV (1.2%) co-infection. Risk factor and demographic distribution varied across co-infection categories. MSM classification was associated with higher odds of all HIV co-infection groups, particularly HBV/HIV (OR 6.8; 95% CI: 5.6, 8.27), while injection drug use was most strongly associated with triple infection (OR 64.19; 95% CI: 55.11, 74.77) and HIV/HCV (OR 23.23; 95% CI: 21.32, 25.31).
Interpretation: Syndemics of substance use, sexual practices, mental illness, socioeconomic marginalization, and co-infections differ among population groups, highlighting avenues for optimal composition and context for health services to meet each population's unique needs.
Funding: BC Centre for Disease Control and Canadian Institutes of Health Research.
Keywords: Co-infection; HIV; Hepatitis B; Hepatitis C; Substance use; Syndemics.
Figures



Similar articles
-
Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada.World J Gastroenterol. 2018 Mar 21;24(11):1216-1227. doi: 10.3748/wjg.v24.i11.1216. World J Gastroenterol. 2018. PMID: 29568202 Free PMC article.
-
Role of unsafe medical practices and sexual behaviours in the hepatitis B and C syndemic and HIV co-infection in Rwanda: a cross-sectional study.BMJ Open. 2020 Jul 12;10(7):e036711. doi: 10.1136/bmjopen-2019-036711. BMJ Open. 2020. PMID: 32660951 Free PMC article.
-
A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia.PLoS One. 2017 Aug 22;12(8):e0183609. doi: 10.1371/journal.pone.0183609. eCollection 2017. PLoS One. 2017. PMID: 28829824 Free PMC article.
-
The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections.J HIV Ther. 2003 Nov;8(4):77-84. J HIV Ther. 2003. PMID: 14671504 Review.
-
Management of hepatitis B and C in HIV co-infected patients.J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S59-65. doi: 10.1097/00126334-200309011-00009. J Acquir Immune Defic Syndr. 2003. PMID: 14562859 Review.
Cited by
-
Concurrent Hepatitis C and B Virus and Human Immunodeficiency Virus Infections Are Associated With Higher Mortality Risk Illustrating the Impact of Syndemics on Health Outcomes.Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa347. doi: 10.1093/ofid/ofaa347. eCollection 2020 Sep. Open Forum Infect Dis. 2020. PMID: 32964065 Free PMC article.
-
Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy.Hepatol Commun. 2019 Jan 10;3(4):478-492. doi: 10.1002/hep4.1307. eCollection 2019 Apr. Hepatol Commun. 2019. PMID: 30976739 Free PMC article.
-
Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: 'Progress toward hepatitis B elimination in Canada'.Can Liver J. 2024 Aug 28;7(3):385-411. doi: 10.3138/canlivj-2024-0014. eCollection 2024 Aug. Can Liver J. 2024. PMID: 40677768 Free PMC article.
-
Approaches to Offering Hepatitis C Treatment at Syringe Services Programs in the United States: A Scoping Review.Open Forum Infect Dis. 2025 Apr 8;12(4):ofaf211. doi: 10.1093/ofid/ofaf211. eCollection 2025 Apr. Open Forum Infect Dis. 2025. PMID: 40290563 Free PMC article. Review.
-
Advancing virtual primary care for people with opioid use disorder (VPC OUD): a mixed-methods study protocol.BMJ Open. 2022 Sep 26;12(9):e067608. doi: 10.1136/bmjopen-2022-067608. BMJ Open. 2022. PMID: 36167365 Free PMC article.
References
-
- Blach S., Zeuzem S., Manns M. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176. - PubMed
-
- Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555. - PubMed
-
- Public Health Agency of Canada Summary: estimates of HIV incidence, prevalence and proportion undiagnosed in Canada, 2014. 2015. https://www.canada.ca/en/public-health/services/publications/diseases-co... Available from:
LinkOut - more resources
Full Text Sources